Some studies showed that using anti-EGFRs in the first-line setting for the right CRC should be avoided when other therapeutic alternatives are available [85] while for wild-type ras mCRC left-sided tumors, chemotherapy plus anti-EGFR drugs is the combination of choice as first-line treatment [86]. Here, EGFR is linked to colorectal carcinoma.